Gotistobart
- Generic Name
- Gotistobart
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05671510
- Locations
- 🇦🇺
Bankstown Hospital - 3305, Bankstown, New South Wales, Australia
🇦🇺Newcastle Private Hospital - 3302, New Lambton Heights, New South Wales, Australia
🇦🇺Mater - 3301, Newstead, Queensland, Australia
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
- Conditions
- Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube Cancer
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05446298
- Locations
- 🇺🇸
Cancer Treatment Centers of America, Phoenix. 403, Goodyear, Arizona, United States
🇺🇸Honor Health, USOR, 406, Phoenix, Arizona, United States
🇺🇸Nuvance Health System, 401, Danbury, Connecticut, United States
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: anti-B7-H3 antibody conjugated to topoisomerase I inhibitorBiological: anti-HER3 antibody conjugated to topoisomerase I inhibitor
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 220
- Registration Number
- NCT05142189
- Locations
- 🇪🇸
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
🇩🇪Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt, Germany
🇪🇸MD Anderson Cancer Center, Madrid, Spain
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
- Conditions
- Metastatic Head and Neck CarcinomaMetastatic Colorectal CancerMetastatic Prostate CancerGastric CancerNon Small Cell Lung CancerMetastatic MelanomaOvarian CancerSalivary Gland CancerUrothelial CarcinomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 733
- Registration Number
- NCT04140526
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The Oncology Institute of Hope and Innovation, Downey, California, United States
🇺🇸University of California at Davis, Davis, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.